Stocklytics Platform
XORTX Therapeutics
XRTX52
$0.92arrow_drop_down4.06%-$0.03
NASDAQ - As of Apr 4, 8:36 PM EDT Market Closed
Penny Stock
XRTX52

$0.92

arrow_drop_down4.06%

Performance History

no data available for performance history chart

There's no data available for performance history chart

no data available for key stats

There's no data available for key stats

no data available for ratios/profitability stats

There's no data available for ratios/profitability stats

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Predicted: just now

info

Analyzed by 1 Wall Street experts, XORTX Therapeutics's 12-month projections average at $14.00, spanning from a high of $14.00 to a low of $14.00. This signifies an 1,449.35% shift from the current price of $0.92.

Analyst Ratings

Buy

Buy
1
100.00%
Hold
0
0.00%
Sell
0
0.00%
Ratings from: April

Last updated: just now

Total: 1
info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

Price$788.17
Perf. (24h)arrow_drop_down0.11%-$0.91
Market Cap$708.73B
Price$538.05
Perf. (24h)arrow_drop_down0.45%-$2.44
Market Cap$494.34B
Price$159.39
Perf. (24h)arrow_drop_down0.39%-$0.62
Market Cap$397.30B
Price$199.86
Perf. (24h)arrow_drop_down0.88%-$1.77
Market Cap$356.69B

About XORTX Therapeutics (XRTX)

XORTX Therapeutics Inc. (XRTX) is a biopharmaceutical company that focuses on the development of innovative therapies for the treatment of kidney diseases, including polycystic kidney disease (PKD) and autosomal dominant polycystic kidney disease (ADPKD). With a dedicated team of scientists and researchers, XORTX is at the forefront of discovering novel treatment options that could potentially improve the lives of millions of patients suffering from these debilitating conditions.
As of the latest market close, XORTX Therapeutics Inc. (XRTX) had a stock price of $10.50 per share. Over the past year, the stock has experienced significant volatility, with a 52-week range of $5.75 to $14.50. This demonstrates the potential for both growth and risk associated with investing in XRTX. It is important for investors to carefully analyze the company's financial performance and market positioning before making any investment decisions.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Allen Warren Davidoff Ph.D.
Headquarters
Alberta Beach
Employees
3
Exchange
NASDAQ
add XORTX Therapeutics to watchlist

Keep an eye on XORTX Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is XORTX Therapeutics's (XRTX) price per share?

The current price per share for XORTX Therapeutics (XRTX) is $0.92. The stock has seen a price change of -$0.04 recently, indicating a -4.06% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for XORTX Therapeutics (XRTX)?

For XORTX Therapeutics (XRTX), the 52-week high is $29.81, which is 3.14K% from the current price. The 52-week low is $0.25, the current price is 268.4% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is XORTX Therapeutics (XRTX) a growth stock?

XORTX Therapeutics (XRTX) has shown an average price growth of -1.65% over the past three years. It has received a score of 95 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying XORTX Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is XORTX Therapeutics (XRTX) stock price performance year to date (YTD)?

As of the latest data, XORTX Therapeutics (XRTX) has a year-to-date price change of -18.47%. Over the past month, the stock has experienced a price change of -2.13%. Over the last three months, the change has been -23.25%. Over the past six months, the figure is -39.81%.
help

Is XORTX Therapeutics (XRTX) a profitable company?

XORTX Therapeutics (XRTX) has a net income of -$2.16M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$4.81M. Furthermore, the EBITDA is -$2.85M.
help

What is the market capitalization of XORTX Therapeutics (XRTX)?

XORTX Therapeutics (XRTX) has a market capitalization of $2.97M. The average daily trading volume is 0.94, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level